Peptide Knowledge Base · Cognition

Cerebrolysin: what it is, what the evidence says, and its real status

The most-studied peptide in the nootropic conversation, 70-plus human studies and decades of clinical use abroad in stroke and dementia.

Can you actually get it?

Plain-English verdict: No availability record.

Regulatory status: No regulatory record.

How does Cerebrolysin work?

A standardized mix of low-molecular-weight neuropeptides and amino acids proposed to mimic neurotrophic-factor activity supporting neuronal survival and repair.

What it does — and what it does not do

What it does: Studied extensively abroad for recovery after stroke and in dementia; the evidence-forward entry in the cognition cluster.

What it does not do: It is not US-approved or available here, and trial quality across the literature is mixed.

How honest is the evidence?

Evidence grade B — Good human evidence.

70+ human studies abroad; heterogeneous quality; not US-approved

A grade measures how much human evidence exists, not whether a molecule is good, safe, or worth your interest. Read our grading methodology for what each grade means.

What we still don't know: Trial quality is heterogeneous; US regulatory path and standardized benefit are unsettled.

WADA status: Not prohibited.

How it is taken

What the literature reports for clinical use abroad: IM or IV courses. Educational only, no dose figures.

Who should not take it

Not US-approved; clinician-managed where used; discuss seizure history and allergy. Not characterized for general use here.

Sources

Cerebrolysin stroke/dementia trial literature (used clinically abroad; quality varies)

Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker for status.

Join the founding list →

Embed this card on your site · free, CC BY 4.0, no key.

Last reviewed Jun 18, 2026 · Peptós.LIFE · Not medical advice.